Meningococcal burden of disease in Argentina: 10 years epidemiologic review.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
01 08 2023
Historique:
medline: 25 8 2023
pubmed: 24 8 2023
entrez: 24 8 2023
Statut: ppublish

Résumé

Invasive meningococcal disease (IMD) is an uncommon but serious and potentially fatal condition, mainly affecting infants. In 2017, Argentina introduced a vaccination program against serogroups A, C, W and Y (MenACWY) for infants aged 3, 5 and 15 months and adolescents aged 11 years. The objective of this study was to review the burden of IMD in Argentina in 2010-2019. Data were obtained from national surveillance databases, and the study estimated IMD incidence, mortality, case-fatality rates, and serogroup distributions across age groups. A total of 1,972 IMD cases were reported in the study period, with the highest incidence in infants aged < 1 year. Incidence peaked in 2013 and subsequently declined. Mortality rates were 18 times higher in infants than in other age groups, reflecting the high impact of IMD in this age group. The case-fatality rate was 8.5% on average and increased with age. The proportion of notified cases with serogroup identification increased over the period, reaching 91% in 2019. The most common serogroups over the study period were serogroup B (48%) and serogroup W (42%), with an increase in B relative to W since 2015. In infants aged < 1 year, the proportion of serogroup B increased in recent years, reaching around 70% of characterized cases in 2018-2019. These results show the dynamism of IMD and indicate the importance of vaccination at an early age and offering protection against predominant serogroups. These data are valuable to support evidence-based decision-making in healthcare.

Identifiants

pubmed: 37614151
doi: 10.1080/21645515.2023.2237391
pmc: PMC10453991
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2237391

Références

J Adolesc Health. 2016 Aug;59(2 Suppl):S3-S11
pubmed: 27449148
Rev Med Chil. 2013 Aug;141(8):959-67
pubmed: 24448851
Microbiology (Reading). 2002 Jun;148(Pt 6):1813-1819
pubmed: 12055301
Vaccine. 2019 May 9;37(21):2768-2782
pubmed: 30987851
Popul Health Metr. 2013 Sep 10;11(1):17
pubmed: 24016339
Wkly Epidemiol Rec. 2011 Nov 18;86(47):521-39
pubmed: 22128384
J Clin Microbiol. 2004 Apr;42(4):1764-5
pubmed: 15071043
Infect Dis Ther. 2018 Dec;7(4):421-438
pubmed: 30267220
Pediatr Infect Dis J. 2017 Mar;36(3):296-300
pubmed: 27902653
PLoS One. 2011;6(6):e20675
pubmed: 21731621
Rev Panam Salud Publica. 2017 Dec 20;41:e118
pubmed: 31391828
Epidemiol Infect. 2019 Nov 29;147:e311
pubmed: 31779718
BMC Public Health. 2022 Feb 23;22(1):380
pubmed: 35197024
J Clin Microbiol. 2000 Feb;38(2):855-7
pubmed: 10655397
Hum Vaccin Immunother. 2023 Dec 31;19(1):2186111
pubmed: 37017273
Int J Infect Dis. 2019 Aug;85:37-48
pubmed: 31085314
Vaccine. 2019 Oct 31;37(46):6915-6921
pubmed: 31585728

Auteurs

Silvina Neyro (S)

Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, Argentina.

Analia Urueña (A)

Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Universidad Isalud, Buenos Aires, Argentina.

Adriana Efron (A)

Servicio Bacteriología Clínica, Laboratorio Nacional de Referencia de Meningococo, Instituto Nacional de Enfermedades Infecciosas-ANLIS "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.

Carolina Rancaño (C)

Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, Argentina.

Maria E Pannunzio (ME)

GSK, Buenos Aires, Argentina.

Maria B Seoane (MB)

GSK, Buenos Aires, Argentina.

Jorge A Gomez (JA)

GSK, Buenos Aires, Argentina.

Norberto Giglio (N)

Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH